Concepedia

Economic benefits of subcutaneous trastuzumab administration: A single institutional study from Karolinska University Hospital in Sweden

Elham Hedayati, Lionel Fracheboud, Vaidyanathan Srikant, David Greber, Susanne Wallberg, Christina Linder Stragliotto

PLoS ONE · 2019 · 36 citations · 12 references

DOIFull text

Open access

Abstract

Data from this study showed that the shift from trastuzumab IV to SC formulation resulted in significant economic effects in terms of departmental resources related to time, direct monetary cost savings, and infrastructural revenue gains.

References

12

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

Dennis J. Slamon, W. Eiermann, Nicholas J. Robert et al. · New England Journal of Medicine · 2011 · 2.7K citations · Full text

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

Luca Gianni, Tadeusz Pieńkowski, Young‐Hyuck Im et al. · The Lancet Oncology · 2011 · 2.3K citations

, , +7

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

David Cameron, Martine Piccart, Richard D. Gelber et al. · The Lancet · 2017 · 1K citations · Full text

, , +7

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

Aron Goldhirsch, Richard D. Gelber, Martine Piccart et al. · The Lancet · 2013 · 498 citations

, , +7

Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial

Gustavo Ismael, Roberto Hegg, Susanne Muehlbauer et al. · The Lancet Oncology · 2012 · 337 citations

, , +6